AZN: Year-To-Date and Q3 2017 Results Announcement

AstraZeneca PLC
9 November 2017 07:00

Year-To-Date and Q3 2017 Results
An improved sales performance as the pipeline-driven transformation gathered pace

Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/9881V_1-2017-11-8.pdf

This information is provided by RNS
The company news service from the London Stock Exchange

END

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com